Oncternal Therapeutics (NASDAQ:ONCT) Coverage Initiated by Analysts at StockNews.com

Equities research analysts at StockNews.com began coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT) in a research note issued on Monday. The brokerage set a “hold” rating on the stock.

Several other research firms have also commented on ONCT. Northland Securities reaffirmed a “market perform” rating and issued a $2.00 price target on shares of Oncternal Therapeutics in a report on Thursday, September 12th. Brookline Capital Management reissued a “hold” rating on shares of Oncternal Therapeutics in a report on Thursday, September 12th. Finally, Northland Capmk downgraded Oncternal Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, September 12th. Four analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $10.00.

Oncternal Therapeutics Stock Performance

ONCT opened at $0.53 on Monday. Oncternal Therapeutics has a 12-month low of $0.53 and a 12-month high of $13.14. The firm has a 50 day moving average of $0.86 and a two-hundred day moving average of $3.13. The firm has a market capitalization of $1.56 million, a PE ratio of -0.05 and a beta of 1.18.

Oncternal Therapeutics Company Profile

Oncternal Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial.